Maklumat tambahan indikasi untuk upload pada laman web Year 2013

Products Approved For Additional Indication (DCA 261 – 28 Februari 2013)

NO	PRODUCT (ACTIVE INGREDIENT)	ADDITIONAL INDICATION	MARKETING AUTHORIZATION HOLDER
1.	1.1 Xamiol Gel [Calcipotriol hydrate 50mcg & Betamethasone dipropionate 0.643mg (equivalent to 0.5mg betamethasone)]	 Indication: Topical treatment of scalp and non-scalp plaque psoriasis vulgaris in adults. Posology: Xamiol Gel should be applied to affected areas once daily. The recommended treatment period is 4 weeks for scalp areas and 8 weeks for "non-scalp" areas. 	DKSH MALAYSIA SDN BHD 74, Jalan Universiti, P.O.Box 77, 46200 Petaling Jaya, Selangor.
2.	 2.1 Votrient Film-Coated Tablet 200mg [Pazopanib Hydrochloride 217 mg (equivalent to pazopanib 200mg)] 2.2 Votrient Film-Coated Tablet 400mg [Pazopanib Hydrochloride 433 mg (equivalent to pazopanib 400mg)] 	 Indication: Votrient is indicated for the treatment of patients with advanced Soft Tissue Sarcoma (STS), who had received prior chemotherapy. Limitation of use: The efficacy of Votrient for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors has not been demonstrated. Posology: The recommended dose of Votrient for the treatment of STS is 800mg orally once daily. 	GLAXOSMITHKLINE PHARMACEUTICAL SDN. BHD. Level 6, Quill 9, 112, Jalan Semangat, No.8, Persiaran Tropicana, 46300 Petaling Jaya, Selangor.